Cerimon Pharmaceuticals, Inc. Acquires European Rights to its Topical Diclofenac Sodium Patch
11/10/2009 6:15:39 AM
More...
|
Cerimon Pharmaceuticals, Inc. Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
2/25/2009 9:07:47 AM
More...
|
Cerimon Pharmaceuticals, Inc. Appoints James S. Shannon, M.D., to Board of Directors
12/2/2008 10:16:27 AM
More...
|
Cerimon Pharmaceuticals, Inc. Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9/11/2008 6:35:32 AM
More...
|
Cerimon Pharmaceuticals, Inc. Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
7/9/2008 7:58:16 AM
More...
|
Cerimon Pharmaceuticals, Inc. to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
3/10/2008 8:01:01 AM
More...
|
Cerimon Pharmaceuticals, Inc. Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
1/16/2008 7:18:12 AM
More...
|
Cerimon Pharmaceuticals, Inc. Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
1/4/2008 8:24:34 AM
More...
|
Cerimon Pharmaceuticals, Inc. to Present at the 2007 Biotechnology Industry Organization (BIO) Investor Forum
10/5/2007 10:11:19 AM
More...
|
Cerimon Pharmaceuticals, Inc. Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
10/2/2007 8:11:16 AM
More...
|
|